Literature DB >> 16230905

Technical report and preliminary clinical data of a novel catheter for luminal re-entry after subintimal dissection.

Benjamin Wiesinger1, Hermann Steinkamp, Claudius König, Gunnar Tepe, Stephan H Duda.   

Abstract

RATIONALE AND
OBJECTIVES: The objective of this study was to evaluate the safety and the effectiveness of the Outback catheter for intraluminal re-entry after subintimal dissection in the crossing of chronic arterial occlusions.
METHODS: This study was a proof-of-concept feasibility. Ten patients with totally occluded arteries in the iliac artery to the distal femoral artery (mean occlusion length, 13.1 cm; range, 5-25 cm) were treated with the novel catheter. After successful re-entry, PTA or PTA plus stenting was performed.
RESULTS: No perforations, dissections, lacerations, or device complications occurred. The procedural re-entry success rate with the Outback catheter was 50% (5/10 patients).
CONCLUSIONS: Although the Outback catheter is safe, the percentage of intraluminal reaccess should be ameliorated through engineering improvements because there is some evidence to suggest that subintimal recanalization could produce improved long-term results.

Entities:  

Mesh:

Year:  2005        PMID: 16230905     DOI: 10.1097/01.rli.0000185640.48786.f6

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  2 in total

1.  Strategies for successful percutaneous revascularization of chronic total occlusion of the femoropopliteal arteries when the antegrade passage of a guide wire fails.

Authors:  Hui Jin Lee; Sang Woo Park; Il Soo Chang; Hae Jeong Jeon; Jeong Hee Park
Journal:  Korean J Radiol       Date:  2012-06-18       Impact factor: 3.500

2.  Outcomes of endovascular treatment for patients with TASC II D femoropopliteal occlusive disease: a single center study.

Authors:  Xiangjiang Guo; Guanhua Xue; Xiaozhong Huang; Hui Xie; Wei Liang; Jiwei Zhang; Feng Lin; Tianping Yao
Journal:  BMC Cardiovasc Disord       Date:  2015-05-29       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.